Composition containing branched-chain amino acids

Patent metadata

Field	Value
Publication number	US-12186359-B2
Application number	US-202017619739-A
Country	US
Kind code	B2
Filing date	Jun 29, 2020
Priority date	Jun 28, 2019
Publication date	Jan 7, 2025
Grant date	Jan 7, 2025

Abstract

The present invention relates to compositions comprising branched-chain amino acids (BCAA) and the dipeptide L-Alanyl-L-alanine and their use for improving the performance and recovery during physical activity and for the prevention and/or treatment of muscle wasting associated to pathological or age-related conditions.

First claim

The invention claimed is:

1. A composition comprising branched-chain amino acids (BCCAs) L-Leucine, L-Valine and L-Isoleucine in combination with peptide L-Alanyl-L-alanine.

2. The composition according to claim 1 , wherein the weight ratio L-Leucine: L-Valine: L-Isoleucine is between 2:1:1 and 8:1:1.

3. The composition according to claim 2 , wherein the weight ratio L-Leucine: L-Valine: L-Isoleucine is 2:1:1 or 4:1:1 or 8:1:1.

4. The composition according to claim 1 , wherein the weight ratio L-Leucine: L-Valine: L-Isoleucine: L-Alanyl-L-alanine is between 2:1:1:1 to 2:1:1:3.6.

5. The composition according to claim 4 , wherein the weight ratio L-Leucine: L-Valine: L-Isoleucine: L-Alanyl-L-alanine is 2:1:1:2.5 or 2:1:1:2.

6. The composition according to claim 1 , which is a dietary supplement.

7. The composition according to claim 1 , which is a pharmaceutical composition.

8. The composition according to claim 1 , which is packaged for oral administration.

9. The composition according to claim 1 , containing the following amounts of BCAAs and dipeptide per unit dose: between 0.6 and 1 g of L-Leucine, between 0.3 and 0.5 g of L-Isoleucine, between 0.3 and 0.5 g of L-Valine and from 0.5 g to 1.5 g of L-Alanyl-L-alanine.

10. The composition according to claim 9 , containing the following amounts of BCAAs and dipeptide per unit dose: 0.8 g of L-Leucine, 0.4 g of L-Isoleucine, 0.4 g of L-Valine and 0.8 g of L-Alanyl-L-alanine.

11. A method of preventing, ameliorating and/or treating muscle wasting associated with:
i. pathological conditions;
ii. age-related conditions; or
iii. malnutrition, immobility or fasting,

in a subject in need thereof, comprising administration of the composition according to claim 1 .

12. The method according to claim 11 , wherein the pathological condition is selected from the group consisting of neuromuscular degenerative disorders; chronic obstructive pulmonary disorder; cancer-associated cachexia; diabetes; renal failure; cardiac failure; Cushing syndrome; sepsis; burn injuries; uremia; cirrhosis; and AIDS.

13. The method according to claim 11 , wherein the age-related condition is sarcopenia.

14. A method of improving muscular performance and/or recovery, and/or to reducing muscular fatigue before, after or during physical exercise in a subject in need thereof, comprising administration of an effective amount of the composition according to claim 1 .

15. The method according to claim 12 , wherein the neuromuscular degenerative disorder is muscular dystrophy or muscular atrophy.

Assignees

• Dompe Farm Spa

Inventors

• Allegretti Marcello
• Aramini Andrea
• Bianchini Gianluca

Classifications

• A61K31/223

  of alpha-aminoacids · CPC title

• A61K31/198

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• A23L33/175

  Amino acids · CPC title

• A23L33/18

  Peptides; Protein hydrolysates · CPC title